Chlorasquin is a thymidylate synthetase inhibitor (Ki ≈ 4.9 μM) and a folate antagonist; it can be used to evaluate the efficacy of Methotrexate (HY-14519); due to its stronger binding affinity to dihydrofolate reductase than Methotrexate under alkaline pH conditions, it shows potential for research as an anti-psoriatic agent.